N
Google TrendCOVENTRY VS NEWCASTLE (2000+) — Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Google Trends:coventry vs newcastle2000+levante - sevilla2000+servicio de control de inmigración y aduanas1000+indigo girls500+afc champions league200+what's on netflix200+essie fall nail polish trends 2026200+champions league schedule500+
Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Ribociclib as First-Line" (30 stories)

Top Headline Story

118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS)
Lead StoryCancerNetworkgeneral
May 12

118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS)

<a href="https://news.google.com/rss/articles/CBMiogJBVV95cUxQdkd1OUREWDZCcF9pazhZYVZtYUg3cW85Q2syclYxVllFWkJLMHVzR1g5NHhZUkp4VEYwVkFyTVgyd0h4XzFJdXNOYmd1VkVGSURlMUJRbjFxQ1dOcGRjcWUyWXNEeVpuRWxqVDNpTExvVzVqR29GdnFXNEdiMUR6SDNJWkNoanJNdGwtY3R6cnNzQlZMYm1EeTZTSXdNNng5U3RNVjRWWGZhOVpTaTV3QzI1LVEtYnN5MzVQOEdxaklveFhTOWx2YXlNLXR3bmZxX2lpSUZORk83eDVuaWRWTDRNUVpld0FvNnRCNEhyNEhrNHpXak8wZVYyeExIVzZNdXFRZk5sdEJoRDFaSUo5bjRXcFpvOEFHekEyMURybEZYdw?oc=5" target="_blank">118 Pooled Analysis of Patients Treated With 1st-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) in the MONALEESA (ML) Studies: Long-Term Progression-Free Survival (PFS)</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryRelated Trends

Google Trends & Trending Search Intelligence

Real-time search volume
2000+26m ago

coventry vs newcastle

Premier League LIVE: Coventry City vs Newcastle United - build-up, team news, score, text commentary & match stats

Filter stories
2000+26m ago

levante - sevilla

Levante - Sevilla en directo

Filter stories
1000+26m ago

servicio de control de inmigración y aduanas

"La cosa se está poniendo tensa": manifestantes se enfrentan a agentes migratorios en Oregon

Filter stories
500+26m ago

indigo girls

Indigo Girls cancel show after tour bus driver dies in highway crash

Filter stories

Search Results for "Ribociclib as First-Line"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Early ctDNA Dynamics Predict PFS With First-Line Ribociclib Plus Letrozole in HR+/HER2− Advanced Breast Cancer
DocWireNewsgeneral

Early ctDNA Dynamics Predict PFS With First-Line Ribociclib Plus Letrozole in HR+/HER2− Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi5AFBVV95cUxQX1RKcEFGUEVfbjZoMVE4dlhSZEtNVU9DNklhOEptUzgwM0tUakp6YnNtSnAyeTJVVS1qNmNjUkc5UFNDZ2VXSkVLcGJpYm1LZC11NVhUTVVaeEVHTnJ5RlJXcGE2N05PaURzVjExVEw4ZmY2a0lDRG80MHVTRm1NVEFsbU43cnE5YkZkbkxFZzJ2WFlLa1JwQko4OWJtempaYU5KYVVzRWNoQUFkMS1DUllKWVZxRzVYRUVmMnU4ajJJUVlsVy03ZlNXd0R4cVVTQjRtUEh0TzFTS0NldEJ4aEliR1U?oc=5" target="_blank">Early ctDNA Dynamics Predict PFS With First-Line Ribociclib Plus Letrozole in HR+/HER2− Advanced Breast Cancer</a>  <font color="#6f6f6f">DocWireNews</font>

Read Full StoryMore like this
Ribociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer
Oncodailygeneral

Ribociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiZ0FVX3lxTE5GR0VrR3dYSnVtZGJSVVZ3bkY5dG96V25aOWdjSGVMWkV4cE5PaVNXSlFCNmw1bmYyeDUweU9kVF9fbmZPbXdBS2RmMXVER1VaY0pNRHVRbFNaNzdPeVEzQlEwOV9DcnM?oc=5" target="_blank">Ribociclib Plus Aromatase Inhibitor Delays Postprogression Events in HR+/HER2− Metastatic Breast Cancer</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
MONALEESA Data Reveal Robust Long-Term Disease Control With Ribociclib
Pharmacy Timesgeneral

MONALEESA Data Reveal Robust Long-Term Disease Control With Ribociclib

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPVnRZTmZ6U19YMVdBU1JKQjgyaHJCNk5hTVhMWVhTTVkxQVk5MXptZE5sUkxyVmo1MG9leGM0cDVDNlh3RmRESVVWdVNCbmJpVDI4NkJxZ0VoZjl6WTFhd2JZWUNNSnhfRDBVUHd6NVc0Ym9kdDlybHpHUVp6eG9IY2tubDYxdVJ1dkVZQmVjRUdjTmlONFdUSWU5MG5VcHEyVWw4elZpbG0?oc=5" target="_blank">MONALEESA Data Reveal Robust Long-Term Disease Control With Ribociclib</a>  <font color="#6f6f6f">Pharmacy Times</font>

Read Full StoryMore like this
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
The New England Journal of Medicinegeneral

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE8xa2xLeUoyeElCUFc2QjVScm81TnBKYy0zUkFRVjVRSGZ5eVFzQmhYb2RVUXR6aUNia3A0ajgtd0JENWJsTGRLM09saWlDb3RNZlBWZE9kT0JlcDNNbEZYbg?oc=5" target="_blank">Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer</a>  <font color="#6f6f6f">The New England Journal of Medicine</font>

Read Full StoryMore like this
106 Treatment Durations, Subsequent Treatments, and Switching of First-Line Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with HR+/HER2− Metastatic Breast Cancer in US Routine Clinical Practice
CancerNetworkgeneral

106 Treatment Durations, Subsequent Treatments, and Switching of First-Line Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with HR+/HER2− Metastatic Breast Cancer in US Routine Clinical Practice

<a href="https://news.google.com/rss/articles/CBMizgJBVV95cUxNS05tWWtQN1BhR0lUTG9XS3loMnlsVERqOE00c29YSTd5d0RGTlVjZGVtc01WZWt1bjdpRFhhcXRPWW9xQzRTR0JpZXA5NGxLOUFjYXh6WEg4UlNqaHB6Q2hZZERRVXYyZzNWN2w1Y2NmbmZYU0plTzVfa1VGTmFodk5NYlEydTFqWEZub1VRMDdrTkVaQjVHd1lFN0RvZU9qYzJON3o3RlhzZlRYdmFVMzRvbXBWMmNDNzZpMHF5enhXYV9qTWlFTlFaLWdlVnZZM2Z1U0hJRFlGbUllZ3BsSkRmVnJZcDZuYXZCUzdpNnR5akt3alRpUV9XVWlEdGZsakx1ejZLMV9CYXRDOHVRNk1pckdvZF9vaHF3TFR3VFVjWVNxUU4tVWhxaERBNTlZZU80TEloa0FMbEVRcHg5U1p1TU1DUWFhRmZIS1V3?oc=5" target="_blank">106 Treatment Durations, Subsequent Treatments, and Switching of First-Line Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with HR+/HER2− Metastatic Breast Cancer in US Routine Clinical Practice</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Paolo Tarantino: U.S. Real-World Outcomes After First-Line Ribociclib in HR+/HER2− Metastatic Breast Cancer
Oncodailyworld

Paolo Tarantino: U.S. Real-World Outcomes After First-Line Ribociclib in HR+/HER2− Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiYkFVX3lxTE5NSUJ1cHd3STZhVjdzenprVlRjYk9ldVhlYTRFWWMwWDFMSEpqX2Q0a2h1ZVJWQS1naTdzVTBZaUEtQmwwdUo0NzRIdFBPcXhSeTJrLTdVSERaVmVfdDJ6QlNn?oc=5" target="_blank">Paolo Tarantino: U.S. Real-World Outcomes After First-Line Ribociclib in HR+/HER2− Metastatic Breast Cancer</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Olema Presents Palazestrant OPERA-02 Trial at SABCS 2025
The Clinical Trial Vanguardgeneral

Olema Presents Palazestrant OPERA-02 Trial at SABCS 2025

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPdG5QTzZJaFcxLWpGdkRPeEI1dExDa1JnQ0w4NVE3emt0eHdhdHpOOHlSNVU2RnNROGNmTDdsSGRJR2U1SGJMTHJyOVFsMXhUUjBkR3h4UGJ0Q040VzhLdWdlTFpBSFNQQjBZdlJ0SktWbms0aThQemJQYmEyaFgyel80ZGRrNmR1dUQzaG9nZGszbmxQUERiWDRzcWFlTE9HeVE?oc=5" target="_blank">Olema Presents Palazestrant OPERA-02 Trial at SABCS 2025</a>  <font color="#6f6f6f">The Clinical Trial Vanguard</font>

Read Full StoryMore like this
First-Line Ribociclib at 400 vs 600 mg in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
The ASCO Postgeneral

First-Line Ribociclib at 400 vs 600 mg in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOc3hmREVYYllCS2pWRGtaVFlqaWhpTGhxOFREYTdGWi1tcGQ4a29TV0h5c201UDFieDJOclJRQjZSMWY3SzNyMzF4aFYxckMyQm5hSzNFd2VLbDFtVnVXWmlKRjJaVnJuZkZmOWFha2pXWXBManBBOXBueHBKVUs3OUhmVS13M2lLUUM4T1JfXzhreXRaMjNIM016ZkQ4aHd4LWt5Wkc1aEd1MjJBU3RncFZCQTZHUVBOX2RmOEl2c2xhOVBhcERBdGJzck1qQ1Jpel9qUG92VWN6emVl?oc=5" target="_blank">First-Line Ribociclib at 400 vs 600 mg in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study | Scientific Reports
Natureworld

Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study | Scientific Reports

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFBxcVJNSVNmcnBJbGUxTElJRmlQTzZDdzh0UmEzd2I3aFBDbzR2R2hkcC12eng5M2NtT1oxMExteGRxeEZqZy1ETFM5RUFvWTJ6NWh3a2U1MW8zNHQyRUFn?oc=5" target="_blank">Association between obesity and outcomes of first-line CDK4/6 inhibitor therapy in metastatic breast cancer: a multicenter real-world study | Scientific Reports</a>  <font color="#6f6f6f">Nature</font>

Read Full StoryMore like this
Ribociclib as First-Line Treatment for Metastatic Breast Cancer
National Cancer Institute (.gov)general

Ribociclib as First-Line Treatment for Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMifkFVX3lxTE9OM3l6amhmOXNXLVk2UE53Z2g3OVpUZ1drOGtJdlhRUFNwbDEtTlMydXM4Z043TE1rQngtVGhTMTFKNXlnNFBDTERLakJNN3p2T09Uczc0YUhyUVdjMmFYaFlTbWpfbHNZdmZacHZJWXhNdFkxRGNaSE5QUUVkZw?oc=5" target="_blank">Ribociclib as First-Line Treatment for Metastatic Breast Cancer</a>  <font color="#6f6f6f">National Cancer Institute (.gov)</font>

Read Full StoryMore like this
First-Line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer
The ASCO Postgeneral

First-Line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiiwJBVV95cUxQaktZRFN3TmRWdmlSZV9jTU5nTV9DeXZnQ2tCcmI0eWtIUERlajN6dXQydGMzQ2Q1cU5BdFhVQUs4Q1V6dklLaHBMOGxQZklTRGdLaWIzTnVLMFM2c1JTSHpQRmhsbEMxckUtLWNFelV3TEFFQkV6Z3NuU3BCU1VWMlJyYlBmbGZ0Y3lmU0U0dFJIc21va2RhbXFmVTd6TzdFcG5uWUpJT3FOZ2s1MUxHQjYxUGQ5ajg2WTllZHhfNVJnUG1BSkU2T01tbHZVWGYtdWQ3MThoeHBySlFsN3VMbXlxWUZJVER3dEdrcF90WXJKTUJOT0FvQzNUMmplaURRd09zY3dEdnppSUE?oc=5" target="_blank">First-Line Ribociclib Plus Endocrine Therapy May Be More Effective Than Combination Chemotherapy in Patients With Aggressive Breast Cancer</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
NEJMgeneral

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1KMVVsYVM1MkhrNzYycWRvekVZZWJlOG41b2tJbGt4WWFxN3pVekFFTGZ0U0V6LWxIQlFzMmdQRkZiMWxwZHBCbkNKYmViSzZnR2UxWEIyZ0FHdE5fSmdubQ?oc=5" target="_blank">Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer</a>  <font color="#6f6f6f">NEJM</font>

Read Full StoryMore like this
Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer
National Cancer Institute (.gov)general

Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxPTGFyeUEyVDJwRURNTExwOVIxb2NlS1h2MzZNWHU4dzhwTExCV0ZZZ1E1TWdhUDE1ODdLc2NsRkNlQWUyenVLRUgwYVRkNW5XdGhpS3NQQ2UzcGdsRGZUeWJtTFVwY3BBVW9UMEVjcFZnbFNHY2czdjVGTnRjVkI3aTllRmhLRmRmT0xSLWZyYkRHeXdySVB6djhlR1RCTklvcGc4OHNDZ0NQaHk4UU5DaXdvQU8?oc=5" target="_blank">Combo of Ribociclib, Letrozole Improves Survival in Advanced Breast Cancer</a>  <font color="#6f6f6f">National Cancer Institute (.gov)</font>

Read Full StoryMore like this
18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources
CancerNetworkgeneral

18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources

<a href="https://news.google.com/rss/articles/CBMi4wFBVV95cUxNaW9Gby1Hd3MtaDJUeXFHTmlsbGw4NUZjZE1yZmxnT21yVkNwTEJsWHA0Sk9fcDhqSVZzaGhlU0RYX0l1bkJBZkxaYjdVV0hoanlyMF9OVkhuZXVBM1kxYzBzYl9FVGY2b1pxT2pQeEZNaW9QcnJjNVR1LWhsOFNfdy1Ma3BRclZKaFAta1ZQeE9MaHpMeF9PZ1ZHeUpQUmF5MmNHclYwa0s4ZE9CRzVyWG5uUGlsU2pLMWtNcVJIbndHNi14Tk1Mb2xYNWxjeHZUbEl3RVVFcXBhZC1CZGllSHdMdw?oc=5" target="_blank">18 Tolerability of First-Line Treatment With Ribociclib for Metastatic Breast Cancer Using 2 Large US Data Sources</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
MONALEESA-2: Overall Survival Benefit With First-Line Ribociclib Plus Letrozole
The ASCO Postgeneral

MONALEESA-2: Overall Survival Benefit With First-Line Ribociclib Plus Letrozole

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQbjh3RjdhNGlhNkRraVdyNUJNSnc4bE4zUWdrN3RST3h4S1M0eXFTMWdKRjMzU2NnaDlhdzVDbF96cFJoZ1JMekxyVFJxNkIxUGwwa29kMnZRT2EwMTFnN3FDS2p2R0RsNzY4NHotOXdxRkJHTExiUHc2WmhiRERwQWl2djdSTGNDTmo3ejlNWXBKaUlVSUV6ZDk1Z01yek9Cck1aaUM0OVVCN2dsS2g5ay1nbXBqTzBKS2dLaWVsdmI?oc=5" target="_blank">MONALEESA-2: Overall Survival Benefit With First-Line Ribociclib Plus Letrozole</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
First-line Ribociclib Plus Letrozole Improved Survival for Postmenopausal HR+, HER2- Advanced Breast Cancer
CancerNetworkgeneral

First-line Ribociclib Plus Letrozole Improved Survival for Postmenopausal HR+, HER2- Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPdVNqSjNuZUVNTTlUNzF3dHpieFAzOEpMemdpclhUUmt3NVp6YTcyS084QXFqT0NRa3dwUVRDR2o5bTg4bVhRc0JITFFaRVhGRUFxOTlUVjl3VlRzVVROWDZkRVNiNTZKT1N5XzlRV0RhTld0ZTBkUVczdHBTNWRIbTFQcU90ajhGSU43WnlsVDQyRkJXaGQ0ekxzajZxRGNnUU5TWk5xUV9mT3lCMmhCdGlvejliQmc0dUlEQjlUSTEtalBrNkI1b1RHSXZMY09wSm1tVVlLUQ?oc=5" target="_blank">First-line Ribociclib Plus Letrozole Improved Survival for Postmenopausal HR+, HER2- Advanced Breast Cancer</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting
The ASCO Postgeneral

MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting

<a href="https://news.google.com/rss/articles/CBMi7AFBVV95cUxOWEI2dWFNZmVuUVdNbUM1ZVdmV2ExRjFjWGF3UXVNX3d6NVlIeEJDNVZYeEExRzFLRWpBWUVnSlZ0Y3N4NlY2MlNXMmxHcnRRNEFOWDJrajZHZEp4c3JIQVJSWTA2Q2FJMHVJTFF2ak9xOXRsN3EtRzRPdzNmSWc4clJyYmpZTVJBTlFVRkQ4UkVtX0VRWGhGS0h2YW5oMndkdHl2emdlenRzekZ3ckYyZk10aWpMMFdIeTBIMDkzMjZxSmtIY1I4VzZuanpjaEM1OU5tbUs5eHpXY3I0aHZDaE4wRE1EckZXSkVROQ?oc=5" target="_blank">MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting</a>  <font color="#6f6f6f">The ASCO Post</font>

Read Full StoryMore like this
FDA Approves Ribociclib for First-Line Metastatic Breast Cancer
CancerNetworkgeneral

FDA Approves Ribociclib for First-Line Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPVTRpYzFvbnZQb0U5UTRFTUxuQ2dBMXBEYjZIR1p0b3BpRFBsOHpORHB5Q0JubzRBNC11X2ZJLTNrOVd3eEc4Rkp2QUdCQ2VmQzYtRUhpaVVsYXRiLVNueEZTc2phSV9DMExrMFEwV2R3ajMxNE83ZTdXQUkxXzMzNHlnMzZyZ0JaNlY3U05SZXRvT0gzdVQ2WEhR?oc=5" target="_blank">FDA Approves Ribociclib for First-Line Metastatic Breast Cancer</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
First-line Ribociclib-AI Combo Associated with Better Symptom-Related QOL Vs Abemaciclib-AI in HR+/HER2− Advanced Breast Cancer
CancerNetworktech

First-line Ribociclib-AI Combo Associated with Better Symptom-Related QOL Vs Abemaciclib-AI in HR+/HER2− Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxOTjNUdWpIUjRuQTdoQzhiVDdKaWxMX0ZFVVViUksta2FBbWhVSGN5ckxXRGtCWlYtdFI3c0U4dkMzOE1JU20wRk1HZFVxOGZGelpCT3RYUW84ZTQzdDlDaTZWNUl0QjVCMERWUUhzajY2ZE5NTldHQ2d5UDk1ZnBnX0VHdy1QYjlsV1plbk5CNGQ1R0dnakZzODRIQVlvT2JhcldmM3NTYWhTTks3MDRhRko1YmxyZGZLOWVsakpscDVHS25FMFBNa090VzJsdHBMTXV6dEdJbXQ5dTBuZ2dOZ3otekptQ2dkTzZORUh2aWdUQQ?oc=5" target="_blank">First-line Ribociclib-AI Combo Associated with Better Symptom-Related QOL Vs Abemaciclib-AI in HR+/HER2− Advanced Breast Cancer</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgrou
CancerNetworkgeneral

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgrou

<a href="https://news.google.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?oc=5" target="_blank">14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgrou</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Making Sense of PALOMA-2 and MONALEESA-2 Data for the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer
ASCO Daily Newsgeneral

Making Sense of PALOMA-2 and MONALEESA-2 Data for the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOYzNlTGNCS2JDcmF1Z2lHM3puSlYzOEV5QjlLY29obnBIeWdhMWM4dFRlS3lUUFk5Q25EdHBLWGZxSUJNbkhEQTlad1FoUzdTZFlJQXROalJUSEF0cE82SU1OeC1KZFNRSUM1bk9feS1wS245ZS1JME1YRHpNOHo1WmN2Rk52am16LU0wYXlKUzFvWVFBTmRra0VjUzllY3dzcm9GanV0MVZUUEVHeWVCdGV3?oc=5" target="_blank">Making Sense of PALOMA-2 and MONALEESA-2 Data for the Treatment of HR-Positive/HER2-Negative Metastatic Breast Cancer</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies
CancerNetworkgeneral

28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies

<a href="https://news.google.com/rss/articles/CBMiuwJBVV95cUxQc1JuTWhLQXkxc0dzOVcyZ3pvUlUzbFJ1M1JVMW5kdGstT1AtTnZsbW9DR1ZVZmw4azByaXg0d2UxaUhabGhfVTVKVWI1ek9sdi1VbUFJNTNzeFBySVdJRzZwdDlkcUw3dkVOMWFlMWtzX0JHOS1DUmMtU1hVeEh4N0hmdExNalFaUE9LS0NmcXUzZUpjbUNpNmdaZU9XUkxSZlhsX3VQclpmTk83YUFEX0hmeXAtdFJQRDlIck5vWmxiRjIzLUgwQ1ZGdFNmajl4Z1dRUFgxenJNLXpsR0lwdWdES2djYldVeGlCSEo1NFdUNWp6ODEydlpPcnhzeXNUUkZ6djRUTzJoUU1PaTBMd0syZ3VPSnVQNWY1WWVETElPTVA3X3hKcC1sX2pUMm9rZXdyS0tFU1FsQkk?oc=5" target="_blank">28 Pooled Analysis of Post- Progression Treatments After Firstline Ribociclib + Endocrine Therapy in Patients With HR+/HER2− Advanced Breast Cancer in the MONALEESA-2, -3, and -7 Studies</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Ribociclib Improves OS in Postmenopausal, HR+, HER2- Advanced Breast Cancer
Cancer Therapy Advisorgeneral

Ribociclib Improves OS in Postmenopausal, HR+, HER2- Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNMldoS1NBWGJQVU10emNxdDdXOTY5dzE0d0JQNmdxaHBJVGZwaGVIWWpYQ09CcUJ0QlBSUmhLdzkzOUVsWVZUaDFYUWIzYXZ0UXlra1ZaOFc0dEVybkZlSUtmZzVsSjdfRHhqekFKaHJBM3dIODQzZFVWV1B0NGVkd1lTblRnRmlhUXFIaTVWb2xLN0JIV2dRVU9XRmRZSlM4SmhKbWNpeXp2UXUwa3pYeU02TWJJQQ?oc=5" target="_blank">Ribociclib Improves OS in Postmenopausal, HR+, HER2- Advanced Breast Cancer</a>  <font color="#6f6f6f">Cancer Therapy Advisor</font>

Read Full StoryMore like this
Combination Ribociclib and Aromatase Inhibitors in Metastatic Breast Cancer: A Retrospective Real-World Analysis
DocWireNewsworld

Combination Ribociclib and Aromatase Inhibitors in Metastatic Breast Cancer: A Retrospective Real-World Analysis

<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxOaW1jc2Zub24xaUxaM0FaVnRZMVdyWXFkZEZKTl9nZFpvck1zLVEydjhpbnk0c2hidGVITFBfdlBCREw1RFE3cTBwRDRUYlBMVmJyYVpiUU9MVFh2RjZuRkIzZnpFTVMtNlpzUmJ0ZGt5QmlVYm41ZVFxNXpOaUZrNmNIWVhOc2xSRnVkTF9HeTZlNmVhVDFTZTYyNGk3VXNYVGFkQjdlb2JDQTUtcFlkXzFMc3c0NXJfTkJIcHJXWmRDSzR2dElraGstblZRMlVTbXVSRXJkLXdFNUc5?oc=5" target="_blank">Combination Ribociclib and Aromatase Inhibitors in Metastatic Breast Cancer: A Retrospective Real-World Analysis</a>  <font color="#6f6f6f">DocWireNews</font>

Read Full StoryMore like this
Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports
Frontiersgeneral

Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports

<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxPZy13akIybHRpZ2s5Q2l6TmxGUnJDbGV2YktXc296dHQ4dGpHc3ZWX1BrZmZiY3RZWEdaS0xtMXpYN3VlT2dVM2NWTmVEc1NZSXg4WldfaWNmSTJFZXlnY2xNZnBUT1FzTENUVUxTOWpIX3BkTy1ScF82RldITEtnVHR0Vm5OWWtlOG1fbWtB?oc=5" target="_blank">Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports</a>  <font color="#6f6f6f">Frontiers</font>

Read Full StoryMore like this
Selecting Patients for Frontline CDK4/6 Inhibitors in Metastatic Breast Cancer
ASCO Daily Newsgeneral

Selecting Patients for Frontline CDK4/6 Inhibitors in Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxQLTU1cjN6ZURlTGlNaXJCTnZ5bmM5Ykt4Wm01M3J4R1pkeHJPMEJXZDQ1cHlCazgxTGdfcmpwdEt6MVZYMTRqWTVPYjhYLW1LRDUyWWJob0tnaTNUVm83MGhIcXdYMnYzY0hhaUNodXd3YTZJZHRHSUhFTFBrSFVUNHpZbHJyOGNkVHZ3M1J4bWlXOWJjd0VPUjNlcmN5aGtjd290ODVqTmE?oc=5" target="_blank">Selecting Patients for Frontline CDK4/6 Inhibitors in Metastatic Breast Cancer</a>  <font color="#6f6f6f">ASCO Daily News</font>

Read Full StoryMore like this
MONALEESA Trial: The Study That Quietly Rewrote Survival in HR-Positive Metastatic Breast Cancer
Oncodailygeneral

MONALEESA Trial: The Study That Quietly Rewrote Survival in HR-Positive Metastatic Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE1BeXQ4bkF2eS1ET2VSZTNjMm9xbmc4Q0xLUjRrVTF4TmxNaUZTTC1RVkFYTUxpSWJHVmo5Mi1OVjc0WEM5WFVfQnRHZ3JQRDhDY0pzVlpHUjFJN0ZJMEdxUA?oc=5" target="_blank">MONALEESA Trial: The Study That Quietly Rewrote Survival in HR-Positive Metastatic Breast Cancer</a>  <font color="#6f6f6f">Oncodaily</font>

Read Full StoryMore like this
Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer
CancerNetworkgeneral

Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPUklBcFo5UXM3VWJqYWl0dkd2WElDNmV3bkxpd29BaVplM1kzTUhQeXQwZVIwVk50aXpUVEhDdTJMUVNwQ05Pa05pRkNjWTFmSEF3bGFpTmpfMzRWSzZWU01zYmkzTjh6dVd3eUZ2a2MzdUJTRWExUnctMmJhS25kR2ZBeVI4V29vakg1d0NHcEJwb3JINC1fNlNhWXc5c2Y2azRJVWZtbFE?oc=5" target="_blank">Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer</a>  <font color="#6f6f6f">CancerNetwork</font>

Read Full StoryMore like this
Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer
OncLivegeneral

Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNNWtqVVZuQ2NId1Z5N0RYaXdvc1pRZTQxckRXNXIycmQ1ci1Hb3lfWndZeXRjeW42MlA4cGJFRGVFbWk2NFBHY0doeUl3ckhqc1ZqWmVyNXFCODZ0aEVDTk44Wl9VOGJLZV8zQy1LNm9sLUpBenNjUFNac1UybU5yazBRWUFydTJOZHRHZVFFOHBJLU9Ia190ZUFaX1pLZVB5ZlNUUV96ZmVQTWE1dkZDaGIxYVlub244ZjR4NEVGX1c?oc=5" target="_blank">Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer</a>  <font color="#6f6f6f">OncLive</font>

Read Full StoryMore like this
"Ribociclib as First-Line" — Live Google News Trends & Headlines